## **Supplementary Methods**

## Flow cytometric monocyte HLA-DR expression analysis

Peripheral blood samples were collected in EDTA-containing tubes which were kept on ice and rapidly routed to the laboratory. Whole blood (50  $\mu$ l) was stained with 20  $\mu$ l of QuantiBrite anti-HLA-DR/Monocyte mixture (QuantiBrite anti-HLA-DR PE (clone L243)/Anti-monocytes (CD14) PerCP-Cy5.5 (clone M $\Phi$ P9), Becton Dickinson, San José, CA) at room temperature for 30 min in the dark. Samples were the lysed using the FACS Lysing solution (Becton Dickinson) for 15 min. After a washing step, cells were analyzed with BD FACSCanto-II flow cytometer and FACSDiva software version 8 (BD Biosciences, San José, CA). Monocytes were first gated out from other cells on the basis of CD14 expression and mHLA-DR expression was then measured on their surface (mono-parametric histogram) as median of fluorescence intensity related to the entire monocyte population (as recommended by manufacturer). These results were then transformed in AB/C (number of antibodies fixed per cell) thanks to calibrated PE-beads (BD QuantiBrite-PE Beads, Becton Dickinson).

## Statistical analysis

Primary objective was analyzed using a non-supervised analysis: hierarchical ascendant clustering (HAC) [13]. The goal of this method is to cluster the entire analyzed population. This use an iterative way to group observations in clusters, by a distance and an aggregation method. The end of iterations results in a unique cluster made up of the whole observations. We can illustrate results with a dendrogram.

HAC need two parameters a priori:

- A distance: in this study the Euclidian distance

- An aggregation method: in this study the Ward's linkage method [10]

HAC results in all the possible clusters with the previously parameters, and defined variables. In our case, variables are the following: Leucocytes G/L, Lymphocytes G/L, total CD3<sup>+</sup> T cells G/L, total CD4<sup>+</sup> T cells G/L, total CD4<sup>+</sup> T cells G/L, total CD3<sup>+</sup> T cells %, total CD4<sup>+</sup> T cells %, total CD4<sup>+</sup> T cells %, CD4<sup>+</sup>/CD8<sup>+</sup>, CD3-CD56<sup>+</sup> %, naive CD4<sup>+</sup> T cells %, total CD4<sup>+</sup> T cells %, effector CD4<sup>+</sup> T cells %, naive CD8<sup>+</sup> T cells %, central memory CD4<sup>+</sup> T cells %, effector CD8<sup>+</sup> T cells %, CD8 CDRA<sup>+</sup> CCR7 %, regulatory T cells %, CD4<sup>-</sup>CD8<sup>-</sup>/CD3<sup>+</sup> %, CD57<sup>+</sup>/CD4<sup>+</sup> %, CD57<sup>+</sup>/CD8<sup>+</sup> %, CD56<sup>+</sup>/CD4<sup>+</sup> %, CD56<sup>+</sup>/CD4<sup>+</sup> %, CD56<sup>+</sup>/CD4<sup>+</sup> %, CD56<sup>+</sup>/CD8<sup>+</sup> %, CD56<sup>+</sup>/CD8<sup>+</sup> %, total B cells G/L total B cells %, transitional B cells %, naive B cells %, natural memory B cells %, total NK cells G/L, total NK cells %, CD16<sup>-</sup> CD56<sup>-</sup> %, total monocytes %. We added age, which might be a variation factor for some of the lymphocyte subpopulations [12].

HAC was implemented using Stata 15 (StataCorp, College Station, TX, USA), with the command cluster 'wardslinkage'. The optimal number of clusters was choosing using selection criterions of Calinski-Harabasz and Duda-Hart, with the following command: 'cluster stop'.

A biological meaning of the clusters was analyzed by screening the values of every parameter, between all clusters. ANOVA F-test was conducted for parameters with a Gaussian distribution, and a non-parametric Mann-Whitney test was run for other distributions. For significant results, a specific cluster by cluster tests were conducted to identify the significantly different cluster. This was conducted using Student tests for Gaussian distributions, Wilcoxson tests for others. Only high significant results were discussed, to take part of the risk of error inflation, due to multiplicity of tests.





## **S1 Table.** Classification of severity.

Characteristics	Class of severity
no O <sub>2</sub> requirement	mild disease
$O_2 \leq 2L/min$	mild disease
$O_2 > 2L/min$	severe disease
ICU admission	severe disease
LTE	severe disease
decease	severe disease

LTE : Limitation of Therapeutic Effort

S2 Table. Panel of four antibody combinations used in the study.

Fluoro- chrome Tube	FITC	PE	PerCP or PerCP- Cy5.5	PE-Cy7	APC	APC-Cy7 or APC- H7	V450	V500
1	CD3	CD56 and CD16	CD45	CD4	CD19	CD8	HLA-DR	х
2	CD57	CD8	CD45	CD3	CD45RA	Х	CCR7	Х
3	IgD	CD10	CD38	CD27	IgM	CD19	Х	Х
4	CD3	CD127	CD45	CD56	CD25	CD16	CD7	CD45

|--|

CD	Fluorochrome	Clone	Isotype	Supplier	Catalogue N°
CD3	FITC	SK7	Ms IgG1, κ	<b>BD</b> Biosciences	644611
CD4	PE-Cy7	SK3	Ms IgG1, κ	<b>BD</b> Biosciences	644611
CD8	APC-H7	SK1	Ms IgG1, κ	<b>BD</b> Biosciences	644611
CD19	APC	SJ25C1	Ms IgG1, κ	<b>BD</b> Biosciences	644611
CD16	PE	B73.1	Ms IgG1, κ	<b>BD</b> Biosciences	644611
CD56	PE	NCAM16.2	Ms IgG2b, κ	<b>BD</b> Biosciences	644611
CD45	PerCP	2D1	Ms IgG1, κ	<b>BD</b> Biosciences	644611
HLA-DR	V450	L243	Ms IgG2a, κ	<b>BD</b> Biosciences	655874
CD8	PE	B9.11	Ms IgG1	Beckman Coulter	A07757
CD4	PerCP-Cy5.5	SK3	Ms IgG1, κ	<b>BD</b> Biosciences	332772
CD3	PE-Cy7	UCHT1	Ms IgG1	Beckman Coulter	737657
CD45RA	APC	HI100	Ms IgG2b, κ	<b>BD</b> Biosciences	550855
CD197	VB421	150503	Ms IgG2a	BD Biosciences	562555
			rabit anti-	Agilent	
IgD	FITC	polyclonal	human	technologies	F018901
CD10	PE	HI10a	Ms IgG1, κ	BD Biosciences	332776
CD38	PerCP-Cy5.5	HIT2	Ms IgG1, κ	<b>BD</b> Biosciences	551400
CD27	PE-Cy7	1A4CD27	Ms IgG1	Beckman Coulter	B49205
IgM	APC	G20-127	Ms IgG1, κ	<b>BD</b> Biosciences	551062
CD19	APC-H7	SJ25C1	Ms IgG1, κ	<b>BD</b> Biosciences	641395
CD127	PE	HIL-7R-M21	Ms IgG1, κ	<b>BD</b> Biosciences	557938
CD56	PE-Cy7	N901 (NKH-1)	Ms IgG1	<b>BD</b> Biosciences	A21692
CD25	APC	2A3	Ms IgG1, κ	<b>BD</b> Biosciences	340907
CD16	APC-H7	3G8	Ms IgG1, κ	<b>BD</b> Biosciences	560195
CD7	V450	T701	Ms IgG1, κ	<b>BD</b> Biosciences	642916
CD45	V500	HI30	Ms IgG1, κ	BD Biosciences	560777

**S4 Table.** Cell subsets and corresponding immunophenotypes.

Cell subset	Immunophenotype
T-cell subsets	
Total CD4 <sup>+</sup> T cells	CD3 <sup>+</sup> CD4 <sup>+</sup>
Naive CD4 <sup>+</sup> T cells	CD45RA <sup>+</sup> CCR7 <sup>-</sup>
Central memory CD4 <sup>+</sup> T cells	CD45RA <sup>-</sup> CCR7 <sup>-</sup>
Effector CD4 <sup>+</sup> T cells	CD45RA <sup>+</sup> CCR7 <sup>-</sup>
Regulatory T cells	CD4 <sup>+</sup> CD127 <sup>low</sup> CD25 <sup>high</sup>
Total CD8 <sup>+</sup> T cells	CD3 <sup>+</sup> CD8 <sup>+</sup>
Naive CD8 <sup>+</sup> T cells	CD45RA <sup>+</sup> CCR7 <sup>-</sup>
Central memory CD8 <sup>+</sup> T cells	CD45RA <sup>-</sup> CCR7 <sup>-</sup>
Effector CD8 <sup>+</sup> T cells	CD45RA <sup>+/-</sup> CCR7 <sup>-</sup>
B-cell subsets	
Total B cells	CD19 <sup>+</sup>
Transitional B cells	IgD <sup>+</sup> CD27 <sup>-</sup> CD10 <sup>+</sup> CD38 <sup>high</sup>
Naive B cells	IgD <sup>+</sup> CD27 <sup>-</sup> CD10 <sup>-</sup> CD38 <sup>low</sup>
Natural memory B cells	IgD <sup>+</sup> CD27 <sup>+</sup>
Post germinal memory B cells	IgD <sup>-</sup> CD27 <sup>+</sup> CD38 <sup>low</sup>
Plasmablasts	IgD <sup>-</sup> CD27 <sup>high</sup> CD38 <sup>high</sup>
NK cells	
Total NK cells	CD56 <sup>+</sup> or CD16 <sup>+</sup> and CD3 <sup>-</sup>
Cytotoxic NK cells	CD56 <sup>+</sup> CD16 <sup>+</sup> CD3 <sup>-</sup>
Immunomodulatory NK cells	CD56 <sup>-</sup> CD16 <sup>+</sup> CD3 <sup>-</sup>
Inflammatory NK cells	CD56 <sup>+</sup> CD16 <sup>-</sup> CD3 <sup>-</sup>
Monocytes	
Total monocytes	CD45 <sup>high</sup> SSC <sup>intermediate</sup>
Non-conventional monocytes	CD16 <sup>+</sup>

	Cluster 1	Cluster 2	Cluster 3	Cluster 4	Cluster 5	p-value
Leucocytes, G/L	5.7 [3.7;8.2]	6.3 [4.6;10.3]	8.5 [5.9;10.8]	5.4 [4.1;7.8]	6.1 [3.9;7.1]	$0.089^{1}$
Lymphocytes, G/L	0.9 [0.7;1.5]	0.9 [0.6;1.4]	0.6 [0.4;1.2]	1.2 [0.7;1.5]	0.8 [0.6;1.3]	0.271
Lymphocytes, %	18 [12;28]	1 4 [7;23]	7 [6;15]	19 [11;24]	17 [10;23]	$0.018^{1}$
T-cell subsets						
Total CD3 <sup>+</sup> T cells, G/L	0.7 [0.5;1.1]	0.6 [0.4;0.9]	0.4 [0.3;0.7]	0.8 [0.6;1]	0.6 [0.4;0.9]	$0.11^{1}$
Total CD4 <sup>+</sup> T cells , G/L	0.5 [0.3;0.8]	0.4 [0.2;0.6]	0.3 [0.2;0.5]	0.4 [0.2;0.5]	0.4 [0.3;0.6]	0.049 <sup>1</sup>
Total CD8 <sup>+</sup> T cells, G/L	0.2 [0.1;0.3]	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.4 [0.2;0.5]	0.2 [0.1;0.2]	$0.001^{1}$
Total CD3 <sup>+</sup> T cells, %	72 [67;81]	63 [55;71]	67 [59;74]	77 [74;82]	74 [66;83]	p<0.0011
Total CD4 <sup>+</sup> T cells, %	52 (10)	43 (10)	43 (12)	32 (9)	48 (10)	p<0.001 <sup>2</sup>
Total CD8 <sup>+</sup> T cells, %	17 (8)	17 (7)	19 (7)	38 (14)	22 (8)	p<0.001 <sup>2</sup>
CD4+/CD8+	3.1[2;4.9]	2.8 [1.7;3.5]	2 [1.5;3.4]	0.9 [0.8;1.5]	1.9 [1.6;3.6]	p<0.0011
Naive CD4 <sup>+</sup> T cells, %	53 (16)	36 (12)	47 (18)	25 (10)	51 (13)	p<0.001 <sup>2</sup>
Central memory CD4 <sup>+</sup> T	34 (12)	49 (11)	32 (8)	36 (11)	28 (11)	p<0.001 <sup>2</sup>
cells, %						
Effector CD4 <sup>+</sup> T cells, %	12 [8;16]	14 [11;18]	15 [12;18]	35 [32;42]	19 [12;26]	p<0.0011
Naive CD8 <sup>+</sup> T cells, %	46 [32;55]	21 [15;27]	22 [15;33]	7 [5;11]	8 [6;14]	p<0.0011
Central memory CD8 <sup>+</sup> T	11 [7;19]	15 [10;18]	6 [5;12]	5 [3;8]	4 [3;7]	p<0.0011
cells, %						
Effector CD8 <sup>+</sup> T cells, %	44 [36;50]	64 [57;70]	71 [58;75]	87 [81;91]	85 [82;90]	p<0.001 <sup>1</sup>
Regulatory T cells, %	7 [5;8]	9 [7;10]	8 [6;10]	7 [5;9]	7 [6;8]	$0.049^{1}$
CD4 <sup>-</sup> CD8 <sup>-</sup> /CD3 <sup>+</sup> , %	2 [2;4]	3 [2;5]	2 [2;3]	4 [2;4]	2 [1;6]	0.463 <sup>1</sup>
T-cell activation markers	-					
HLA-DR <sup>+</sup> /CD4 <sup>+</sup> , %	6 [5;8]	9 [7;11]	14 [9;19]	14 [12;18]	13 [8;18]	p<0.001 <sup>1</sup>
HLA-DR <sup>+</sup> /CD8 <sup>+</sup> , %	18 [14;27]	31 [26;40]	55 [33;62]	37 [24;50]	53 [31;63]	p<0.001 <sup>1</sup>
<b>T-cell senescence markers</b>						-
CD57 <sup>+</sup> /CD4 <sup>+</sup> , %	1 [1;2]	1 [1;3]	2 [1;4]	16 [11;23]	6 [1;9]	p<0.001 <sup>1</sup>
CD57 <sup>+</sup> /CD8 <sup>+</sup> , %	14 [10;19]	32 [26;44]	18 [13;23]	50 [47;54]	44 [31;54]	p<0.001 <sup>1</sup>
B-cell subsets						-
Total B cells, G/L	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.1 [0.0;0.1]	0.1 [0.0;0.1]	0.049 <sup>1</sup>
Total B cells, %	12 [8;17]	17 [12;23]	17 [10;24]	10 [7;11]	9 [6;12]	$0.001^{1}$
Transitional B cells, %	4 [2;6]	4 [2;6]	1 [1;4]	5 [2;6]	1 [1;3]	p<0.001 <sup>1</sup>
Naive B cells, %	58 (16)	55 (14)	31 (17)	53 (12)	43 (22)	p<0.001 <sup>2</sup>
Natural memory B cells, %	8 [4;12]	8 [4;10]	6 [3;21]	9 [5;14]	6 [4;9]	$0.794^{1}$
Post germinal memory B	12 [8;18]	14 [9;18]	9 [7;16]	13 [9;19]	15 [11;35]	0.0561
cells, %						0.0011
Plasmablasts, %	4 [2;11]	7 [3;12]	29 [23;42]	5 [3;10]	6 [3;14]	p<0.001 <sup>1</sup>
NK-cell subsets	0.1.00.1.0.03	0.1.0.1.0.01	0.1.50.0.0.11	0.1.50.1.0.01		0.571
Total NK cells, G/L	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.1 [0.0;0.1]	0.1 [0.1;0.2]	0.1 [0.1;0.2]	0.571
Total NK cells, %	12 [7;18]	15 [9;25]	14 [8;21]	12 [10;18]	14 [6;21]	0.5951
Cytotoxic NK cells, %	89 [85;94]	89 [79;92]	90 [88;94]	92 [85;96]	92 [90;94]	0.1051
Inflammatory NK cells, %	2[1;4]	3[1;7]	2[1;4]	2[1;3]	2[2;5]	0.661
Immunomodulatory NK	5 [4;9]	6 [4;13]	4 [3;8]	4 [3;7]	4 [2;6]	0.2061
cells, %						
Monocytes	80(20)	75(22)	7 1 (2 7)	7.0 (2.0)	7.2 (2.2)	0.7702
Non conventional	0.0 (3.0)	1.3 (3.3)	<i>1.1 (2.1)</i>	1.0 (3.0)	1.2 (3.3)	0.7792
mon-conventional	12[/;19]	11[/;14]	5 [5;12]	13 [10;17]	14 [10;26]	0.003
multiples, $\%$	42044 (17029)	25218 (17405)	21000 (0796)	11608 (20202)	47150 (10101)	0.0042
Other	+2044 (17038)	23210 (17403)	21009 (9760)	++008 (20302)	4/150 (19101)	0.004
Age	56 [44 6:72 1]	70 [56 6:75 6]	71 [62 3:80 6]	72 [64 1.82 5]	79 [70 8.89 3]	n<0.001 <sup>1</sup>
1150		1 10 100.0.10.01	1 1 1 0 4. J. 0 0. 01		1 1 2 1 1 0 0 0 0 2 11	1 0 20.001

S5 Table. Overall comparison of cellular subpopulations between the clusters.

<sup>1</sup> p-value from Kruskal Wallis test due to non-normality distribution; median [IQR] <sup>2</sup> p-value from F-test Anova due to normality distribution; mean (SD) <sup>3</sup> number of antibodies fixed per cell

S6 Table. Major characteristics of the five clusters of patients.

	Cluster 1	Cluster 2	Cluster 3	Cluster 4	Cluster 5
Age (mean) <sup>1</sup>	56.4	66.6	70.1	72.5	79
Lymphocytes G/L	low	low	low	low	low
CD8 <sup>+</sup> T cells	low	very low	very low	normal	low
Effector CD8 <sup>+</sup> T cells	high	very high	very high	extremely high	extremely high
Effector CD4 <sup>+</sup> T cells	normal	normal	normal	high	normal
CD4 <sup>+</sup> and CD8+ activation	low activation	high	very high	very high	very high
CD8 <sup>+</sup> senescence	low senescence	high	low senescence	very high	very high
CD4 <sup>+</sup> senescence	low senescence	low senescence	low senescence	very high	high
Plasmablasts	normal/high	high	extremely high	high	high
mHLA-DR	normal	normal/low	normal/low	normal	normal
Mortality <sup>2</sup>	0	17.4	9.5	11.1	26.1

<sup>1</sup> p<0.0001 cluster 1 against others; cluster 5 against others <sup>2</sup> p=0.005 cluster 1 against others; p= 0.006 clusters 2 and 5 against others